This animation has been commissioned and funded by Napp Pharmaceuticals Limited and developed in partnership with Guidelines in Practice. Napp Pharmaceuticals Limited suggested the topic for the animation, worked with MGP Ltd to choose and commission the presenter, and approved all materials related to the animation. The views and opinions expressed in the animation are not necessarily those of Guidelines in Practice, its publisher, advisers, or advertisers.
The third joint consensus report on the management of hyperglycaemia in type 2 diabetes by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)1,2 updates the previous position statements with:
- a patient-centric management strategy
- more emphasis on lifestyle management
- new evidence from trials published since 2014
- an approach to the choice of glucose-lowering medication that considers the presence of specific comorbidities.
Professor Melanie Davies (co-chair of the ADA/EASD consensus report) presents this short animation covering:
- changes since the previous 2015 ADA/EASD guidance
- choice of glucose-lowering medications, taking into account new evidence from cardiovascular outcome trials
- five scenarios that affect the choice of second-line therapy.
- Davies MJ, D’Alessio DA, Fradkin J et al. Diabetologia 2018; 61: 2461‑2498. https://doi.org/10.1007/s00125-018-4729-5
- Davies MJ, D’Alessio DA, Fradkin J et al. Diabetes Care 2018; 41: 2669–2701. https://doi.org/10.2337/dci18-0033
Date of preparation: April 2019